Drugs / OPB-51602
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02058017 | Nov 2013 → May 2015 | nasopharyngeal carcinoma | National University Hospital, Singapore | Terminated | No outcome recorded |
| Phase 1 | NCT01344876 | Apr 2011 → Apr 2014 | acute myeloid leukemia, chronic myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma +1 | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01423903 | Feb 2010 → Apr 2013 | cancer of unknown primary site | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01184807 | Dec 2009 → Jun 2013 | cancer | Otsuka Beijing Research Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPB-51602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02058017 ↗ |
| Action | Inhibit | “OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor” PMID 25609248 ↗ Jan 2015 |
| Route | Oral | “OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor” PMID 25609248 ↗ Jan 2015 |
| Target | STAT3 | “OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor” PMID 25609248 ↗ Jan 2015 |